We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Immature Natural Killer Cells Predict Relapse After Cord Blood Transplantation

By LabMedica International staff writers
Posted on 31 Dec 2019
Print article
Image: Schematic diagram of how novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation (CBT) (Photo courtesy of MD Anderson Cancer Center).
Image: Schematic diagram of how novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation (CBT) (Photo courtesy of MD Anderson Cancer Center).
Umbilical cord blood transplantation (CBT) has become an accepted alternative treatment of patients with hematologic cancers or other disorders. Many of the disadvantages of CBT, including limited numbers of total nucleated cells, have been dealt with in significant ways, leading to marked reductions in the time to hematopoietic cell recovery.

Natural killer (NK) cells are highly heterogeneous, with vast phenotypic and functional diversity at the single-cell level. They are involved in the innate immune response against malignant and virus-infected cells. Although the kinetics of T- and B-cell subset recovery after CBT are well-described, much less is known about the recovery of CB-derived natural killer (NK) cells in the post-transplant setting.

Stem transplantation specialists at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) used high-dimensional mass cytometry and the metrics of NK cell diversity to study the NK cell repertoire in serial samples from 43 CBT recipients. A panel comprising 40 metal-tagged antibodies was used for the detailed characterization of NK cells. To assess NK cell cytotoxicity, the team co-cultured NK cells with 51Cr-labeled K562 targets at multiple E:T ratios (20:1, 10:1, 5:1, 1:1); cytotoxicity was measured by target release of 51Cr.

Total RNA was collected from five million NK cells per donor and pooled libraries were sequenced (50-bp paired-end reads generated with the HiSeq 2500 (Illumina, San Diego, CA, USA). Data were acquired on a Helios mass cytometer (Fluidigm, South San Francisco, CA, USA) and fluorescence cytometry data were acquired on BD LSRFortessa X-20 (BD Biosciences, San Jose, CA, USA).

The investigators reported that a higher-diversity index based on single-cell combinatorial phenotypes was significantly associated with a lower risk for relapse after CBT. Cytomegalovirus reactivation was a major factor in the development of a more diverse NK repertoire after CBT. They identified a group of patients whose CB-derived NK cells after transplantation possessed an immature phenotype (CB-NKim), characterized by poor effector function and a low diversity index. Frequencies of CB-NKim of 11.8% or higher during the early post-CBT recovery phase were highly predictive for relapse, a finding that was validated in a second independent cohort of 25 patients. They also showed that the maturation, diversity, and acquisition of effector function by CB-NKim early after CBT were driven by interleukin 15.

The authors concluded that their data indicated that the diversity of the NK cell repertoire after CBT contributes importantly to the risk for subsequent relapse. They suggest that the use of diversity metrics and high-dimensional mass cytometry may be useful tools in predicting clinical outcomes and informing the design of therapeutic strategies to prevent relapse after CBT. The study was published on December 10, 2019 in the journal Blood Advances.

Related Links:
The University of Texas MD Anderson Cancer Center
Illumina
Fluidigm
BD Biosciences


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.